GlassScriptPhysician profile
Stephen M Mooney
NPI 1003815622
$7,086.15
in general payments reported to CMS, 2019-2025
42 companies · $1,143 in 2025
The $1,143 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,204 · 2020: $570 · 2021: $708 · 2022: $953 · 2023: $1,046 · 2024: $1,463 · 2025: $1,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,651.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $877.56 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $707.72 | 2019-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $604.86 | 2019-2025 | Jardiance, Ofev |
| Abbvie INC. | $501.96 | 2021-2025 | |
| Novo Nordisk INC | $490.94 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $383.49 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $368.07 | 2021-2025 | |
| Pfizer INC. | $335.08 | 2019-2025 | |
| Amgen INC. | $313.92 | 2019-2024 | Evenity, Prolia |
| Astellas Pharma US INC | $311.48 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $276.17 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $270.81 | 2019-2025 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $170.98 | 2019-2025 | Zoryve, Seglentis |
| Eisai INC. | $149.07 | 2025 | |
| Sanofi-Aventis U.S. LLC | $137.49 | 2019-2024 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $136.61 | 2022-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Amarin Pharma, INC. | $114.55 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.56 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $85.28 | 2023 | Rexulti |
| Sumitomo Pharma America, INC. | $80.55 | 2024-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $58.17 | 2022-2023 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $57.77 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Esperion Therapeutics, INC. | $51.63 | 2021 | |
| Phathom Pharmaceuticals, INC. | $47.55 | 2023-2025 | Voquezna |
| Lundbeck LLC | $44.53 | 2023 | Rexulti, Vyepti |
| Xeris Pharmaceuticals, INC. | $43.94 | 2023 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $39.40 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.62 | 2022 | |
| Idorsia Pharmaceuticals US INC | $34.87 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $30.98 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Ultragenyx Pharmaceutical INC. | $26.40 | 2023 | |
| Allergan, INC. | $22.69 | 2019-2020 | |
| Nevro Corp. | $20.96 | 2024 | Senza |
| Vanda Pharmaceuticals INC. | $20.90 | 2025 | Fanapt |
| Sage Therapeutics, LLC | $20.66 | 2025 | Zurzuvae |
| Almatica Pharma LLC | $19.92 | 2023 | Gralise, Loreev Xr, Sertraline Hcl |
| Dexcom, INC. | $18.48 | 2024 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $17.63 | 2022 | |
| Genentech USA, INC. | $17.17 | 2020 | |
| Atricure, INC. | $16.86 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $13.11 | 2022 | |
| Inogen, INC. | $4.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Mooney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.